Inhibition of human blood platelet aggregation and the stimulation of nitric oxide synthesis by aspirin

References

• Colman R W, Walsh P N. Haemostasis & Thrombosis. In: Colman R W, Hirsh J, Maeder V J, Salzman E W, eds. Philadelphia, PA: J.B. Lippincott, 1987; 594–605.
   Google Scholar
• Ignarro L J, Harbison R G, Wood K S, Kadowitz P J. Activation of purified soluble guanylate cyclase by endothe-lium – derived relaxing factor from intrapulmonary artery and vein; Stimulation by acetylcholine, bradykinin and arachidonic acid. J Pharmacol Exp Ther 1986; 237: 893–900.
   PubMedGoogle Scholar
• Forstermann U, Mulsch A, Bohme E, Busse R. Stimulation of soluble guanylate cyclase by an acetylcholine – induced endothelium – derived factor from rabbit and canine arteries. Circ Res 1986; 58: 531–38.
   PubMed Web of Science ®Google Scholar
• Dutta Roy A K, Sinha A K. Purification and properties of prostaglandin E1/prostacyclin E1 receptor of human blood platelets. J Biol Chem 1987; 262: 12685–691.
   PubMedGoogle Scholar
• Kanowitz P J. Evidence for the inhibitory role of guanosine 3050 – monophosphate in ADP – induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood 1981; 57: 946–55.
   PubMedGoogle Scholar
• Sinha A K, Acharya K, Bhattacharya S, Mazumder S, Bauman W A, Kahn N N. Prevention of thrombosis in vivo by nitric oxide. Ind J Physiol & Allied Sci 1998; 52(3): 148–61.
   Google Scholar
• Battinelli E, Willoughby S R, Foxall T, Valeri C R, Loscalzo J. Induction of platelet formation from megakaryocytoid cells by nitric oxide. Proc Natl Acad Sci USA 2001 Dec 4; 98(25): 14458–63.
   PubMedGoogle Scholar
• Magazine H I, Chang J, Goumon Y, Stefano G B. Rebound from nitric oxide inhibition triggers enhanced monocyte activation and chemotaxis. J Immunol 2001 Jul; 165(1): 102–7.
   Google Scholar
• Del Maschio A, Evangelista V, Rajtar g, Chen ZM, Cerletti C, de Gaetano G. Platelet activation by polymorphonuclear leucocytes exposed to chemotactic agents. Am J Physiol (Heart Circ Physiol 27) 1990; 258: H870–H879.
   Google Scholar
• Salvemini D, de Nucci G, Gryglewski R J, Vane J R. Human neutrophils and mononuclear cells inhibit platelet aggregation by releasing a nitric oxide-like factor. Proc Natl Acad Sci USA 1989; 86: 6328–32.
   PubMed Web of Science ®Google Scholar
• Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330(18): 1287–94.
   PubMed Web of Science ®Google Scholar
• Steering Committee of the Physicians’ Health study research group: Final report on the aspirin component of the aspirin component of the ongoing physicians health study N Engl J Med 1989; 321: 129–35.
   Google Scholar
• Antman E M, Braunwald E. Acute Myocardial Infarction. Harrison’s Principle of Internal Medicine. McGrawhill Inc., New York, 1998: 1352–65.
   Google Scholar
• The European Atrial Fibrilation Trial study Group: optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. The European Atrial fibrillation Trial Study Group N Engl J Med 1995; 333(1): 5–10.
   PubMedGoogle Scholar
• Robert J, Mayer. Gastrointestinal Tract Cancer. Harrison’s Principle of Internal Medicine. New York: McGrawhill Inc. 1998; 568–578.
   Google Scholar
• Roth G, Majerus P. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975; 56: 624–32.
   PubMed Web of Science ®Google Scholar
• Pederson A K, Fitzgerald G A. Dose-related kinetics of aspirin: presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984; 311: 1206–11.
   PubMedGoogle Scholar
• Di Gaetano G, Cerletti C, Dejana E, Latin R. Pharmacology of platelet inhibition in humans: implications of the salicylate-aspirin interaction. Circulation 1985; 72: 1185–93.
   PubMedGoogle Scholar
• Kahn N N, Mueller Hiltrud S, Sinha A K. Restoration by insulin of impaired prostaglandin E1/I2 receptor activity of platelets in Acute Ischemic Heart Disease. Circ Res 1991; 68: 245–54.
   PubMedGoogle Scholar
• Smith J B, Willis A L. Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biol 1971, Jun 23; 231(25): 235–7.
   PubMedGoogle Scholar
• Rao G H, White J G. Comparative pharmacology of cyclooxygenase inhibitors on platelet function. Prostaglandins Leukot Med 1985; 18(1): 119–31.
   PubMedGoogle Scholar
• Buege, J A, Aust, S D. Microsomal lipid peroxidation. Methods in Enzymology 1978; 52: 302–10.
   PubMedGoogle Scholar
• Sinha A K, Rao A K, Willis J, Colman R W. Inhibition of thromboxaneA2 synthesis in human platelets by coagulation factor Xa. Proc Natl Acad Sci. USA 1983; 80: 6086–90.
   PubMedGoogle Scholar
• Sinha A K, Bhattacharya S, Acharya K, Mazumder S. Stimulation of nitric oxide synthesis and protective role of insulin in acute thrombosis in vivo. Life Sci 1999; 65: 2687–96.
   PubMed Web of Science ®Google Scholar
• Rigg A. Preparation of blood hemoglobins of vertebrates. Methods in Enzymology 1981; 76: 5–15.
   PubMedGoogle Scholar
• Hamberg M, Svensson J, Samuelsson B. Prostaglandin endoperoxides: a new concept concerning the mode of action and release of prostaglandins. Proc Natl Acad Sci USA 1974; 71(10): 3824–28.
   PubMedGoogle Scholar
• Eiroa A M, Marcus A J. Inhibition of platelet reactivity by endothelium derived relaxing factor from human umbilical vein endothelial cells in suspension: blokade of aggregation and secretion by an aspirin-insensitive mechanism. Blood 1991; 78: 1033–40.
   PubMedGoogle Scholar
• David L. Nelson, Michael M. Cox. Lehninger Principles of Biochemistry. 3rd ed. Macmillan Worth, 2000; 785.
   Google Scholar